Home   Business   Article

Abcam strikes antibody deal with NanoString Technologies


By Paul Brackley


Cambridge-based Abcam has agreed a partnership with fellow life science tools provider NanoString Technologies, in Seattle.

Inside Abcam's new HQ on the Cambridge Biomedical Campus. Picture: Keith Heppell
Inside Abcam's new HQ on the Cambridge Biomedical Campus. Picture: Keith Heppell

The deal gives researchers using NanoString’s GeoMx Digital Spatial Profiler access to its collection of more than 6,000 recombinant monoclonal antibodies.

Abcam will manufacture and sell GeoMx-formatted antibodies through its catalog and website directly to GeoMx DSP users.

John Baker, SVP of product portfolio and innovation at Abcam, which recently moved into its new Cambridge Biomedical Campus HQ, said: "We are excited to be partnering with NanoString to support the GeoMx DSP users' ground-breaking research. Our recombinant monoclonal antibodies help ensure robust and quantitative spatial protein analysis of even the most challenging samples and may ultimately accelerate vital biomarker discoveries.”

Brad Gray, president and CEO of NanoString, said: "Researchers using our GeoMx DSP platform often want to customize their analysis. We have partnered with Abcam to facilitate access to their broad portfolio of high quality, validated antibodies to augment our off-the-shelf GeoMx protein panels. Abcam’s proven track record of antibody quality and performance was a key consideration in ensuring the success of our customer’s spatial profiling research.”

John Baker, SVP of product portfolio and innovation at Abcam, which recently moved into its new Cambridge Biomedical Campus HQ, said: "We are excited to be partnering with NanoString to support the GeoMx DSP users' ground-breaking research. Our recombinant monoclonal antibodies help ensure robust and quantitative spatial protein analysis of even the most challenging samples and may ultimately accelerate vital biomarker discoveries.”

Read more

Inside Abcam's new £46million headquarters on Cambridge Biomedical Campus

Abcam expands custom capabilities with acquisition of California-based Calico Biolabs



COMMENTS
()


Iliffe Media does not moderate comments. Please click here for our house rules.

People who post abusive comments about other users or those featured in articles will be banned.

Thank you. Your comment has been received and will appear on the site shortly.

 

Terms of Comments

We do not actively moderate, monitor or edit contributions to the reader comments but we may intervene and take such action as we think necessary, please click here for our house rules.

If you have any concerns over the contents on our site, please either register those concerns using the report abuse button, contact us here.

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies - Learn More